C1orf50 Accelerates Epithelial-Mesenchymal Transition and the Cell Cycle of Hepatocellular Carcinoma
C1orf50 is a novel biomarker of poor prognosis in HCC and a key regulator of oncogenic features such as EMT, cell cycle progression, and stemness. This study highlights the therapeutic potential of targeting C1orf50-related networks in aggressive subtypes of liver cancer.
Authors
- Michael H. A. Roehrl (ORCID: https://orcid.org/0000-0003-4892-1098)
- Shinichi Toyooka (ORCID: https://orcid.org/0000-0002-7588-6745)
- Atsushi Fujimura (ORCID: https://orcid.org/0000-0002-8638-5460)
- Masaki Maekawa (ORCID: https://orcid.org/0000-0003-1064-0469)
- Venessa Chin (ORCID: https://orcid.org/0000-0002-4630-4451)
- Yusuke Otani
- Atsushi Tanaka (ORCID: https://orcid.org/0000-0002-7566-2098)
- Tirso Peña
- Anna Rogachevskaya
Institutions
- UMass Memorial Health Care (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Okayama University (JP)
- Kagawa University (JP)
- UMass Memorial Medical Center (US)
Publication Details
- Journal
- Cancer Genomics & Proteomics
- Published
- 2025-10-28
- DOI
- https://doi.org/10.21873/cgp.20541
- Citations
- 1
- Primary Topic
- Kruppel-like factors research
- Type
- article
- Field-Weighted Citation Impact
- 0.81